Search BRITE hierarchies

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
  L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
    L01 ANTINEOPLASTIC AGENTS
      L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
        L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
          L01FE02 Panitumumab
            D05350  Panitumumab (USAN/INN) <JP/US>

USP drug classification [BR:br08302]
  Antineoplastics
    Monoclonal Antibody/Antibody-Drug Conjugate
      Panitumumab
        D05350  Panitumumab (USAN/INN)

Therapeutic category of drugs in Japan [BR:br08301]
  4  Agents affecting cellular function
    42  Antineoplastics
      429  Miscellaneous
        4291  Other Antitumors
          D05350  Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN)

Drug groups [BR:br08330]
  Antineoplastic
    DG01918  Tyrosine kinase inhibitor
      DG01917  Receptor tyrosine kinase inhibitor
        DG03162  EGFR inhibitor
          D05350  Panitumumab

Drug classes [BR:br08332]
  Antineoplastic
    DG03162  EGFR inhibitor
      D05350  Panitumumab

Target-based classification of drugs [BR:br08310]
  Protein kinases
    Receptor tyrosine kinases (RTK)
      EGFR family
        EGFR [HSA:1956] [KO:K04361]
          D05350  Panitumumab (USAN/INN) <JP/US>

New drug approvals in the USA [br08319.html]
  D05350

New drug approvals in Europe [br08329.html]
  D05350

New drug approvals in Japan [br08318.html]
  D05350

New drug approvals in the USA, Europe and Japan [br08328.html]
  D05350

Pharmacogenomic biomarkers [br08341.html]
  D05350